Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus OLMESARTAN MEDOXOMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus OLMESARTAN MEDOXOMIL.
BENICAR HCT vs OLMESARTAN MEDOXOMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to decreased peripheral vascular resistance and reduced blood pressure.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
20 mg orally once daily, titrate as needed to 40 mg once daily; maximum 40 mg daily.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Terminal elimination half-life: 10-15 hours; reaches steady-state after 3-5 days; clinically allows once-daily dosing.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Renal: 35-50% as unchanged drug; biliary/fecal: 50-65% via bile into feces, primarily as parent drug.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB